Understanding Dostarlimab Prescribing Information: A Guide for Patients and Healthcare Providers
Dostarlimab (brand name: Jemperli) is a medication used to treat certain types of cancers, such as advanced endometrial cancer. It is a type of immunotherapy that helps the body’s immune system fight cancer cells. However, it is important to understand the prescribing information of Dostarlimab before using it.
What is Dostarlimab and how does it work?
Dostarlimab is a humanized monoclonal antibody that binds to a protein called PD-1 (programmed cell death protein-1) on immune cells. PD-1 normally prevents the immune system from attacking healthy cells in the body, but some cancer cells use PD-1 to evade the immune system. By binding to PD-1, Dostarlimab blocks the signal that prevents the immune system from attacking cancer cells.
Who can use Dostarlimab?
Dostarlimab is approved by the U.S. Food and Drug Administration (FDA) for the treatment of certain types of endometrial cancer. It is given to patients who have received prior treatment for their advanced or recurrent cancer and whose cancer has progressed despite treatment with other therapies. It is not currently approved for other types of cancer or for use in patients who have not received other treatments.
What are the possible side effects of Dostarlimab?
Like all medications, Dostarlimab can cause side effects, some of which can be serious. The most common side effects include fatigue, nausea, diarrhea, and rash. More serious side effects can include inflammation of the lungs, liver, kidneys, or other organs. Patients should contact their healthcare provider immediately if they experience any symptoms of an allergic reaction, such as difficulty breathing, swelling, or hives.
How is Dostarlimab administered?
Dostarlimab is given as an intravenous infusion (IV), or injection into a vein, over a period of 30 minutes every three weeks. Patients should receive the first infusion in a healthcare setting where they can be monitored for any potential allergic reactions. The healthcare provider will monitor the patient for possible side effects during and after the infusion.
Conclusion
Dostarlimab is a promising new therapy for certain types of endometrial cancer. It works by blocking a protein that cancer cells use to evade the immune system. It is important for patients and healthcare providers to understand the prescribing information for this medication, including its possible side effects and administration protocol. If you have questions about Dostarlimab or any other medication you are taking, talk to your healthcare provider.
